Lamisil At Spray
NDC Package 84485-3605-4

View Billable Units, 11-Digit Conversion Format, and RxNorm mappings
Table of Contents
    1. Package Information
    2. Frequently Asked Questions

Package Information

Lamisil At (terbinafine hydrochloride) sprays is a medication used to treat a variety of fungal skin infections such as ringworm, athlete's foot, and jock itch. This formulation utilizes a spray delivery system. Marketed by Karo Healthcare Inc., this product is identified by NDC 84485-3605 and is authorized under FDA application NDA021124.

Identification & Billing

NDC Package Code
84485-3605-4
Package Description
120 g in 1 CAN
Product Code
84485-3605
11-Digit Billing Format
84485360504
RxNorm Crosswalk

Clinical Specifications

Proprietary Name
Lamisil At
Non-Proprietary Name
Terbinafine Hydrochloride
Substance Name
Terbinafine Hydrochloride
Dosage Form
Spray - A liquid minutely divided as by a jet of air or steam.
Administration Route
Topical - Administration to a particular spot on the outer surface of the body. The E2B term TRANSMAMMARY is a subset of the term TOPICAL.
Active Ingredient(s)
TERBINAFINE HYDROCHLORIDE 1 g/100g
Pharmacologic Class
Usage Information
This medication is used to treat a variety of fungal skin infections such as ringworm, athlete's foot, and jock itch. This medication is also used to treat a skin condition known as pityriasis (tinea versicolor), a fungal infection that causes a lightening or darkening of the skin of the neck, chest, arms, or legs. Terbinafine is an antifungal that works by preventing the growth of fungus.

Regulatory & Marketing

Labeler Name
Karo Healthcare Inc.
Product Type
Human Otc Drug
FDA Application #
NDA021124
Marketing Category
NDA - A product marketed under an approved New Drug Application.
Start Marketing Date
12-10-2025
Listing Expiration
12-31-2026
Exclude Flag
N
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 84485-3605-4 identifies a specific commercial package of 120 g in 1 can of Lamisil At, a human over the counter drug labeled by Karo Healthcare Inc.. This spray is formulated for topical use and contains terbinafine hydrochloride as the active substance.

Is this product currently listed with the FDA?

Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Karo Healthcare Inc. on December 10, 2025. The current certification is valid through December 31, 2026.

What are the primary indications for this medication?

This medication is used to treat a variety of fungal skin infections such as ringworm, athlete's foot, and jock itch. This medication is also used to treat a skin condition known as pityriasis (tinea versicolor), a fungal infection that causes a lightening or darkening of the skin of the neck, chest, arms, or legs. Terbinafine is an antifungal that works by preventing the growth of fungus.

How is this Karo Healthcare Inc. product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 84485360504. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-4-1)
84485-3605-4
11-Digit CMS (5-4-2)
84485-3605-04

Note: The zero is added to the Package segment to maintain the 5-4-2 structure.